1. Home
  2. ORIS vs INDP Comparison

ORIS vs INDP Comparison

Compare ORIS & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ORIS

Oriental Rise Holdings Limited Ordinary Shares

HOLD

Current Price

$1.52

Market Cap

3.7M

ML Signal

HOLD

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

HOLD

Current Price

$2.95

Market Cap

4.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ORIS
INDP
Founded
2014
2000
Country
China
United States
Employees
N/A
N/A
Industry
Farming/Seeds/Milling
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.7M
4.0M
IPO Year
2024
N/A

Fundamental Metrics

Financial Performance
Metric
ORIS
INDP
Price
$1.52
$2.95
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
180.5K
1.7M
Earning Date
04-30-2026
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.01
N/A
Revenue
$12,317,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$163.69
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.14
$1.65
52 Week High
$57.00
$47.60

Technical Indicators

Market Signals
Indicator
ORIS
INDP
Relative Strength Index (RSI) 96.29 61.48
Support Level $0.06 $2.19
Resistance Level $0.11 $3.15
Average True Range (ATR) 0.05 0.28
MACD 0.13 0.10
Stochastic Oscillator 85.91 83.77

Price Performance

Historical Comparison
ORIS
INDP

About ORIS Oriental Rise Holdings Limited Ordinary Shares

Oriental Rise Holdings Ltd is an integrated supplier of tea products in China. It is principally engaged in the business of planting, cultivating, processing, and selling processed tea. The company currently produces and sells three categories of products: roughly processed white tea, roughly processed black tea, and refined tea. The company's business operations are vertically integrated, covering cultivation, processing of tea leaves, and the sale of tea products to tea business operators and end-user retail customers. Geographically, the company generates all of its revenue from its business in the People's Republic of China (the PRC).

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.

Share on Social Networks: